open access

Vol 72, No 5-6 (2004)
ORIGINAL PAPERS
Published online: 2008-02-18
Submitted: 2013-02-22
Get Citation

The influence of asthma and COPD exacerbation on exhaled nitric oxide (FENO)

Marta Maskey-Warzęchowska, Tadeusz Przybyłowski, Katarzyna Hildebrand, Marta Kumor, Katarzyna Górska, Adam Frangrat, Joanna Kucińska, Justyna Kościuch, Ryszarda Chazan
Pneumonol Alergol Pol 2004;72(5-6):181-186.

open access

Vol 72, No 5-6 (2004)
ORIGINAL PAPERS
Published online: 2008-02-18
Submitted: 2013-02-22

Abstract

Exhaled nitric oxide is a marker of airway inflammation and it is significantly decreased by glucocorticosteroid therapy, especially in patients with asthma.
Aim of the study: evaluation of changes in FENO in asthma and COPD exacerbation.
Materials and methods: 17 patients with acute asthma and 19 patients with an exacerbation of COPD were enrolled to the study. FENO (chemiluminescence, on-line, restricted breath technique measurement in accordance with the ATS recommendations) was performed for five consecutive days following admission to hospital. Results of the following additional blood investigations: peripheral white blood cell count, ESR, C-reactive protein level, arterial blood gases, spirometry or peak expiratory flow were also analyzed.
Results: The average value of FENO on admission was 41.5 ± 10.7 ppb (95% CI: 18.8 - 64.2 ppb) asthma patients and 28.6 ± 5.4 ppb (95% CI: 17.4 - 40.0 ppb) in COPD patients. In asthma patients a significant decrease of FENO on the third day of therapy was observed (41.5 vs. 26.1 ppb, p < 0.05). We found a positive correlation between FENO on admission and the peripheral blood eosinophil count. In COPD patients a significant decrease of FENOon the 4th day was noted (28.6 vs. 17.5 ppb, p < 0.05). FENO in both groups was higher than that of 19 healthy volunteers previousty studied in oun laboratory (14.1 ± 4.7 ppb; 95%CI: 11.8 ± 16.4 ppb).
Conclusions: Exacerbations of asthma and COPD are associated with an increased FENO. FENO measurement is a useful tool in the assessment of treatment efficacy. Exhaled nitric oxide may indicate the intensity of allergic inflammation in patients with asthma.

Abstract

Exhaled nitric oxide is a marker of airway inflammation and it is significantly decreased by glucocorticosteroid therapy, especially in patients with asthma.
Aim of the study: evaluation of changes in FENO in asthma and COPD exacerbation.
Materials and methods: 17 patients with acute asthma and 19 patients with an exacerbation of COPD were enrolled to the study. FENO (chemiluminescence, on-line, restricted breath technique measurement in accordance with the ATS recommendations) was performed for five consecutive days following admission to hospital. Results of the following additional blood investigations: peripheral white blood cell count, ESR, C-reactive protein level, arterial blood gases, spirometry or peak expiratory flow were also analyzed.
Results: The average value of FENO on admission was 41.5 ± 10.7 ppb (95% CI: 18.8 - 64.2 ppb) asthma patients and 28.6 ± 5.4 ppb (95% CI: 17.4 - 40.0 ppb) in COPD patients. In asthma patients a significant decrease of FENO on the third day of therapy was observed (41.5 vs. 26.1 ppb, p < 0.05). We found a positive correlation between FENO on admission and the peripheral blood eosinophil count. In COPD patients a significant decrease of FENOon the 4th day was noted (28.6 vs. 17.5 ppb, p < 0.05). FENO in both groups was higher than that of 19 healthy volunteers previousty studied in oun laboratory (14.1 ± 4.7 ppb; 95%CI: 11.8 ± 16.4 ppb).
Conclusions: Exacerbations of asthma and COPD are associated with an increased FENO. FENO measurement is a useful tool in the assessment of treatment efficacy. Exhaled nitric oxide may indicate the intensity of allergic inflammation in patients with asthma.
Get Citation

Keywords

asthma; COPD; exacerbation; nitric oxide

About this article
Title

The influence of asthma and COPD exacerbation on exhaled nitric oxide (FENO)

Journal

Advances in Respiratory Medicine

Issue

Vol 72, No 5-6 (2004)

Pages

181-186

Published online

2008-02-18

Bibliographic record

Pneumonol Alergol Pol 2004;72(5-6):181-186.

Keywords

asthma
COPD
exacerbation
nitric oxide

Authors

Marta Maskey-Warzęchowska
Tadeusz Przybyłowski
Katarzyna Hildebrand
Marta Kumor
Katarzyna Górska
Adam Frangrat
Joanna Kucińska
Justyna Kościuch
Ryszarda Chazan

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Czasopismo Pneumonologia i Alergologia Polska dostęne jest również w Ikamed - księgarnia medyczna

Wydawcą serwisu jest "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl